Summary

Realm Therapeutics has, pending shareholder approval, agreed to be acquired by ESSA Pharma. ESSA’s unattractive bid is in illiquid stock and strongly undervalues Realm’s cash position. Realm’s board and large shareholders clearly have a… Read more